Orphazyme A/S
ORPH
ORPH was delisted on the 30th of March, 2022.
22 hedge funds and large institutions have $4.47M invested in Orphazyme A/S in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
10% more funds holding
Funds holding: 20 → 22 (+2)
5% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $1.7M
22% less capital invested
Capital invested by funds: $5.77M → $4.47M (-$1.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.23M |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$443K |
| 3 |
Renaissance Technologies
New York
|
+$422K |
| 4 |
Optiver Holding
Amsterdam,
Netherlands
|
+$281K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.05M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$552K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$160K |
| 4 |
Morgan Stanley
New York
|
-$83.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$63.6K |
ORPH Hedge Fund Activity: Q3 2021 in Review
22 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q3 2021, worth a combined $4.47M — down 22% from $5.77M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ORPH positions and 7 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $1.23M. The largest seller was Jane Street, exiting entirely with an estimated $1.05M sold.
- 22 institutional investors held Orphazyme A/S (ORPH) as of Q3 2021, up from 20 in Q2 2021.
- Funds reported $4.47M of Orphazyme A/S stock for Q3 2021, down 22% quarter-over-quarter.
- 9 funds opened new Orphazyme A/S positions in Q3 2021 and 7 closed out, a net change of +2 holders.
- The largest Orphazyme A/S buyer in Q3 2021 was Two Sigma Investments, an estimated $1.23M added.
- The largest Orphazyme A/S seller in Q3 2021 was Jane Street, an estimated $1.05M sold.
Based on aggregated 13F filings for Q3 2021.